Katrin Schimke, T. Davis
Apr 1, 2007
Citations
1
Influential Citations
15
Citations
Journal
Current opinion in investigational drugs
Abstract
Daiichi Sankyo Inc is developing rivoglitazone, an insulin sensitizer with peroxisome proliferator-activated receptor gamma agonistic activity, for the potential treatment of type 2 diabetes. By March 2006, phase I/III clinical trials were underway in the US and the EU.